Science and science policy: Regulating “Select Agents” in the age of synthetic biology

Perspectives on Science

Volumn 23, Issue 3, 2015, Pages 280-309

  Méthot, Pierre Olivier ^a  

^a UNIVERSITÉ LAVAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84941135025     PISSN: 10636145     EISSN: 15309274     Source Type: Journal    
DOI: 10.1162/POSC_a_00173     Document Type: Article

References (96)

1. Aldhous, Peter. 2006. “Synthetic Biologists Reject Controversial Guide- lines.” New Scientist, May 23. http://www.newscientist.com/article/dn9211-synthetic-biologists-reject-controversial-guidelines.html#.U2uqVFdW8oM (accessed 8 May 2014)
2. Ashcroft, Richard E. 2005. “Ethics In Science: Proposed Code Does Not Guide Scientists.” Science 307. 21 April. https://www.sciencemag.org/content/307/5717/1881 (accessed 8 May 2014)
3. Atlas, Ronald M. 2002. “National Security and the Biological Research Community.” Science 298: 753-754.
4. Atlas, Ronald M. 2009. “Responsible Conduct by Life Scientists in an Age of Terrorism.” Science and Engineering Ethics 15: 293-301.
5. Atlas, Ronald M., and M. Dando. 2006. “The Dual-Use Dilemma for the Life Sciences: Perspectives, Conundrums, and Global Solutions.” Biosecurity and Bioterrorism 4: 276-286.
6. Bensaude-Vincent, Bernadette. 2013. “Ethical Perspective on Synthetic Biology.” Biological Theory 8 (4): 368-375.
7. Bensaude-Vincent, Bernadette, and Dorothée Benoit-Browaeys. 2011. Fabriquer la vie. Où va la biologie de synthèse? Paris: Seuil.
8. Blaser, M. J., Y. Chen, and J. Reibman. 2008. “Does Helicobacter Pylori Protect against Asthma and Allergy?” Gut 57 (5): 561-567.
9. Blaser Martin J., and Stanley Falkow. 2009. “What Are the Consequences of the Disappearing Human Microbiota?” Nature Reviews Microbiology 7: 887-894.
10. Carlson, Robert H. 2010. Biology is Technology: The Promise, Peril, and New Business of Engineering Life. Cambridge, Mass.: Harvard University Press.
11. Casadevall, Arturo. 2005. National Science Advisory Board for Biosecurity (NSABB). Summary of the Inaugural Meeting, June 30-31, Bethesda: Maryland.
12. Casadevall, Arturo, and David A. Relman. 2010. “Microbial Threat Lists: Obstacles in the Quest for Biosecurity?” Nature Reviews 8: 149-154.
13. Casadevall, A. 2012. “The Future of Biological Warfare.” Microbial Biotechnology 5 (5): 584-587.
14. Casadevall, A., F. C. Fang, and L. A. Pirofski. 2011. “Microbial Virulence as an Emergent Property: Consequences and Opportunities.” PLoS Pathogens 7 (7): 1-3.
15. Casadevall, A., and L. A. Pirofski. 1999. “Host-Pathogen Interactions: Redefining the Basic Concepts of Virulence and Pathogenicity.” Infection Immunology 76: 3703-3713.
16. Casadevall, A., and L. A. Pirofski. 2000. “Host-Pathogen Interactions: Basic Concepts of Microbial Commensalism, Colonization, Infection, and Disease.” Infection Immunology 68: 6511-6518.
17. Casadevall, A., and L. A. Pirfoski. 2002. “What Is a Pathogen?” Annals of Medicine 34: 2-4.
18. Casadevall, A., and L. A. Pirofski. 2003. “The Damage-Response Frame- work of Microbial Pathogenesis.” Nature Review Microbiology 1: 17-24.
19. Casadevall, A., and L. A. Pirofski. 2006. “The Weapon Potential of Human Pathogenic Fungi.” Medical Mycology. December 44: 689-696.
20. Casadevall, A., and L. A. Pirofski. 2008. “The Damage-Response Frame- work of Microbial Pathogenesis and Infectious Diseases.” Pp. 135-146 in GI Microbiodata and Regulation of the Immune System. Edited by Gary B. Huffnagle and Mairi C. Noverr. New York: Springer.
21. Casadevall, A., and L. A. Pirofski. 2009. “Virulence Factors and the Mechanisms of Action: The View from a Damage-Response Frame- work.” Journal of Water and Health 7: 2-18.
22. Center for Disease Control. 2010. Possession, Use, and Transfer of Select Agents and Toxins: Biennial Review. Final Rule. Federal Register 77 (194), October 5.
23. Center for Disease Control and Prevention. 2011. CDC Select Agent Program. Office of Public Health Preparedness and Response.
24. Center for Disease Control and Prevention. 2012. Possession, Use and Transfer of Select Agents and Toxins: Biennial Review: Final Rule 761091. (CDC) and Department of Health and Human Services (HHS). http://www.ncbi.nlm.nih.gov/pubmed/23038847 (accessed 7 May 2014)
25. The Convention on the Prohibition of the Development, Production and Stockpiling of Bacteriological (Biological) and Toxin Weapons and on their Destruction (BTWC). 1975. http://www.fas.org/nuke/control/bwc/text/bwc.htm
26. Dethlefsen, L., M. McFall-Ngai, and D. A. Relman. 2007. “An Ecological and Evolutionary Perspective on Human-Microbe Mutualism and Disease.” Nature 449: 811-818.
27. Dias, M. B., L. Reyes-Gonzalez, F. M. Veloso, and E. Casman. 2010. “Effects of the USA Patriot Act and the 2002 Bioterrorism Preparedness Act on Select Agent Research in the US.” Proceedings of the National Academies of Science 107 (21): 9556-9561.
28. Dreifus, C. 2004. “A Conversation with: Robert C. Richardson; The Chilling of American Science.” New York Times, July 6.
29. Editorial. 2001. “The End of Innocence?” Nature 414 (6861): 235, November 15.
30. Enserink, M. 2005. “Unnoticed Amendment Bans Synthesis of Small-Pox Virus.” Science 307 (5715): 1540a-1541a.
31. Ereshefsky, Mark 2010. “Microbiology and the Species Problem.” Biology and Philosophy 25: 553-558.
32. Falkow, Stanley. 1997. “What Is a Pathogen?” ASM News 63 (7): 359-365.
33. Falkow, Stanley. 2006. “Is Persistent Bacterial Infection Good for Your Health?” Cell 124 (4): 699-702.
34. Fang, Ferric C., and A. Casadevall. 2012. “Reforming Science: Structural reforms.” Infection and Immunity 80 (3): 897-901.
35. Fierer, J., and T. Kirkland. 2002. “Questioning the CDC’s ‘Select Agent’ Criteria.” Science. January 4.
36. Fisher, J. E. 2006. “Stewardship or Censorship? Balancing Biosecurity, the Public’s Health, and the Benefits of Scientific Openness.” The Henry L. Stimson Center, Albuquerque, NM.
37. Fouchier, R. A. M., A. Garcia-Sastre, Y. Kawaoka, et al., 2012. “Pause on Avian Flu Transmission Studies.” Nature 481 (443).
38. Garfinkel, Michele S., D. Endy, G. L. Epstein, and R. M. Friedman. 2007. Synthetic Genomics: Options for Governance. J. Craig Venter Institute, CSIS.
39. Gronvall, G. K. 2008. “Improving the Select Agent Program.” Bulletin of the Atomic Scientists. Opinion, 29 October.
40. Haraway, Donna J. 1985. “Cyborg Manifesto: Science, Technology, and Social-Feminist in the Late 20th Century.” Social Review 80: 65-108.
41. Holtcamp, W. 2012. “One Study, Two Paths. The Challenge of Dual Use Research.” Environmental Health Perspectives 120 (6): 239-242.
42. Imperiale, Michael, and Arturo Casadevall. 2010. “Destruction of Microbial Collections in Response to Select Agent and Toxin List Regulations.” Bio- security and Bioterrorism: Biodefense Strategy, Practice, and Science 8 (2): 151-154.
43. Isenberg, H. D. 1988. “Pathogenicity and Virulence: Another View.” Clinical Microbiology Review 1: 40-53.
44. Jones, K. E., N. G. Patel, M.c A. Levy, A. Storeygard, D. Balk, J. Gittleman, and P. Daszak. 2008. “Global Trends in Emerging Infectious Diseases.” Nature 451: 990-994.
45. Jonsson, C. B., K. S. Cole, C. J. Roy, D. S. Perlin, and G. Byrne. 2013. “Challenges and Practices in Building and Implementing Biosafety and Biosecurity Programs to Enable Basic and Translational Research with Select Agents.” Bioterrorism and Biodefense S3: 015.
46. King, Nicholas. 2004. “The Scale-Politics of Emerging Disease.” Osiris 19: 62-76.
47. King, Nicholas. 2005. “The Ethics of Biodefense.” Bioethics 19 (4): 432-466.
48. Kyl, Jon 1998. “Statement of Hon. Jon Kyl, A U.S. Senator from the State of Arizona.” Pp. 4-5 in Biological Weapons: The Threat Posed by Terrorists - Congressional Hearing before the Subcommittee on Technology, Terrorism, and Government Information. Printed for the Use of the Committee of the Judiciary.
49. Lederberg, Joshua. 2000. “Infectious History.” Science 288 (5464): 287-293.
50. Leduc, James W. 2010. “Preface.” Pp. 7-9 in Sequence-based classification of select agents: A brighter line. National Academies of Sciences, Washington D.C.
51. Leonelli, Sabina. 2014. “Data Interpretation in the Digital Age.” Perspectives on Science 22 (2).
52. Loeve S., B. Bensaude-Vincent, and F. Gazeau. 2013. “Nanomedicine Metaphors: From War to Care. Emergence of an Oecological Approach.” NanoToday 8 (6): 560-565.
53. Maurer, Stephen M., and Sebastian von Engelhardt. 2013. “Industry Self- Governance: A New Way to Manage Dangerous Technologies.” Bulletin of the Atomic Scientists 69 (3).
54. Mendelsohn, Andrew J. 1998. “From Eradication to Equilibrium: How Epidemics Became Complex After World-War I.” Pp. 303-331 in Greater than the Parts. Holism in Biomedicine 1920-1950. Edited by Christopher Lawrence, and George Weisz. Oxford, New York: Oxford University Press.
55. Méthot, Pierre-Olivier, and Samuel Alizon. 2014. “What Is a Pathogen? Towards a Process View of Host-Parasite Interactions.” Virulence 5 (8): 1-10.
56. Méthot, Pierre-Olivier, and Bernardino Fantini. 2014. “Medicine and Ecology: Historical and Critical Perspectives on the Concept of Emerging Disease.” Pp. 214-230 in Nature, Environment, and Quality of Life. Edited by A. La Vergata, G-A. Menant, and J. J. Boersema. Archives Internationales d’Histoire des Sciences. Paris: Brepols Publishers.
57. Miller, S., and Michael J. Selgelid. 2007. “Ethical and philosophical con- siderations of the dual-use dilemma in the biological sciences.” Science and Engineering Ethics 13: 523-580.
58. National Academies of Sciences. 2010. Sequence-based Classification of Select Agents: A Brighter Line. National Academies of Sciences: Washington.
59. National Institutes of Health. 2006. Ending the War Metaphor: The Changing Agenda for Unravelling the Host-Microbe Relationship. The National Academies Press: Washington. http://www.ncbi.nlm.nih.gov/pubmed/21850787 (accessed 8 May 2014)
60. National Institutes of Health, National Science Advisory Board for Biosecurity. 2006. Addressing Biosecurity Concerns related to the Synthesis of Select Agents.
61. National Research Council. 2004. Biotechnology Research in an Age of Terrorism: Confronting the Dual Use Dilemma (Fink Report). National Academies Press: Washington.
62. National Research Council. 2009. A Survey of Attitudes and Actions on Dual Use Research in the Life Sciences: A Collaborative Effort of the National Research Council and the American Association for the Advancement of Science. Washington, DC: The National Academies Press.
63. National Research Council. 2010. Sequence-Based Classification of Select Agents: A Brighter Line. Washington, DC: The National Academies Press.
64. Pallen, M. J., and B. W. Wren. 2007. “Bacterial Pathogenomics.” Nature 449: 835-842.
65. Pirofski, Liise-Anne, and Arturo Casadevall. 2012. “Q&A: What Is a Pathogen? A Question that Begs the Point.” BMC Biology 10 (6): 1-3.
66. Presidential Order. 2009. Executive Order 13486, Strengthening Laboratory Biosecurity in the United States, Federal Register 74(9), January 14. http://www.fas.org/irp/offdocs/eo/eo-13486.htm (accessed 7 May 2014)
67. Presidential Order. 2010. Executive Order 13546, Optimizing the Security of Biological Select Agents and Toxins in the United States 75(130), July 2. http://www.asm.org/index.php?option=com_content&view=article&id=2571 (accessed 7 May 2014)
68. Rambhia K. J., A. S. Ribner, and G. K. Gronvall. 2011. “Everywhere You Look: Select Agent Pathogens.” Biosecurity and Bioterrorism: Biodefense Strategy, Practice, and Science 9 (1): 69-71.
69. Randerson, James. 2006. “Lax Laws, Virus DNA and Potential for Terror.” The Guardian, Wednesday 14 June.
70. Rappert, Brian. 2004. “Responsibility in the Life Sciences: Assessing the Role of Professional Codes.” Biosecurity and Bioterrorism 2 (3): 164-174.
71. Rappert, Brian. 2007. Biotechnology, Security and the Search for Limits. London: Palgrave Macmillan.
72. Rappert, Brian, and Michael Selgelid. (Eds.) 2013. On the Dual Uses of Science and Ethics: Principles, Practices, and Prospects. Canberra: The Australian National University Press.
73. Relman, David A. 2006. “Bioterrorism—Preparing to Fight the Next War.” New England Journal of Medicine 354 (2): 113-115.
74. Relman, David A. 2010. “The Biological Century: Coming to Terms with Risk in the Life Sciences.” Nature Immunology, Commentary 11 (4): 275-278.
75. Resnik, David B. 2010. “Can Scientists Regulate the Publication of Dual Use Research?” Studies in Ethics, Law and Technology 4 (1).
76. Resnik, David B. 2013. Scientific Control over Dual-Use Research: Prospects for Self-Regulation. Pp. 237-253 in On the Dual Uses of Science and Ethics: Principles, Practices, and Prospects. Edited by M. Selgelid and B. Rappert. Canberra: The Australian National University Press.
77. Samuel, G. N., M. J. Selgelid, and I. Kerridge. 2009. “Managing the Unimaginable.” EMBO Report 10 (1): 7-11.
78. Selgelid, Michael J. 2009. “Governance of Dual-Use Research: An Ethical Dilemma.” Bulletin of the World Health Organization 87: 720-723.
79. Selgelid, Michael J., and Lorna Weir. 2010. “The Mousepox Experiment.” EMBO Reports 11 (1): 18-24.
80. Slama, Thomas G. 2011. “IDSA Comments on CDC Proposed Rule Re: Select Agents and Toxins List.” Infectious Disease Society of America, December 2.
81. Soanes, D. M., Intikhab Alam, Mike Cornell, et al., 2008. “Comparative Genome Analysis of Filamentous Fungi Reveals Gene Family Expansions Associated With Fungal Pathogenesis.” PLOS One 3 (6). http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0002300 (accessed 8 May 2014)
82. Sutton, Victoria. 2009. “Smarter Regulations. Commentary on ‘Responsible Conduct by Life Scientists in the Age of Terrorism’.” Science and Engineering Ethics 15: 303-309.
83. Sutton, Victoria. 2010. “The Culture of Science and the Regulation and Litigation of Biodefense Research.” University of St. Thomas Law Journal 6: 523-549.
84. Swiatczak, B., M. Rescigno, and I. R. Cohen. 2011. “Systematic Features of Immune Recognition in the Gut.” Microbes and Infection 13: 983-991.
85. Tumpey, Terrence M., C. F. Basler, P. V. Aguilar, H. Zeng, et al., 2005. “Characterization of The Reconstructed 1918 Spanish Influenza Pandemic Virus.” Science 310 (5745): 77-80.
86. United States. 2001. The USA Patriot Act. PUBLIC LAW 107-56— OCT. 26, 2001. http://www.justice.gov/archive/ll/highlights.htm
87. United States. 1996. Antiterrorism and Effective Death Penalty Act of 1996. Pub. L. No. 104-132, 110 Stat. 1214. http://www.fas.org/irp/crs/96-499.htm (accessed 8 May 2014)
88. United States. 2004. Intelligence Reform and Terrorism Prevention Act of 2004118 STAT. 3638 PUBLIC LAW 108-458—DEC. 17, 2004.
89. US Department of Agriculture. 2002. Agriculture Bioterrorism Act. http://www.aphis.usda.gov/programs/ag_selectagent/ (accessed 8 May 2014)
90. US Department of Health and Human Services. 2009. Screening Frame- work Guidance for Synthetic Double-Stranded DNA Providers. Federal Register Volume 75, Number 197 (Wednesday, October 13, 2010)] [Notices] [Pages 62820-62832] http://www.gpo.gov/fdsys/pkg/FR-2010-10-13/html/2010-25728.htm
91. US Biological Weapon Anti-Terrorism Act. 1989. BWATA, Pub.L. 101-298.
92. US Food and Drug Administration. 1988. Clinical Laboratory Improvement Amendment. http://www.fda.gov/medicaldevices/deviceregulationand-guidance/ivdregulatoryassistance/ucm124105.htm
93. US Food and Drug Administration. 2002. Public Health Security and Bioterrorism Preparedness and Response Act. http://www.fda.gov/regulatoryinformation/legislation/ucm148797.htm
94. Van Aken, Jan. 2006. “When Risks Outweigh Benefit.” EMBO Reports 7. Special Issue: 10-13.
95. Wadman M. 2009. “Driven Out of Research.” Nature. News: Q&A. doi:10.1038/news.2009.957
96. Zylberman, Patrick. 2013. Tempêtes microbiennes. Essai sur la politique de sécurité sanitaire dans le monde transatlantique. NRF Essai, Paris: Gallimard.